false
0001740797
0001740797
2025-11-01
2025-11-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): November
1, 2025
AVANT TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
| |
|
|
| |
|
|
|
Nevada
(State or other jurisdiction of incorporation
or organization)
|
333-225433
(Commission File Number)
|
38-4053064
(I.R.S. Employer Identification Number)
|
c/o Eastbiz.com, Inc 5348 Vegas Drive, Las Vegas,
NV 89108
(Address and telephone number of principal executive
offices)
(Issuer’s telephone number)
(866) 533-0065
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an
emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of
the Act: Not applicable.
| Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
| Not applicable |
|
|
|
|
Item 1.01 - Entry into a Material Definitive Agreement
On November 1, 2025 (the “Effective Date”),
Avant Technologies Inc. (the “Company” and “AVAI”) entered into a Joint Venture and License Agreement with
SGAustria Pte. Ltd., a Singaporean company with registered number UEN 200901830C (the “Austrianova”), collectively referred
to as the “Parties”, setting forth the principal terms of a Joint Venture and License Agreement (the “Agreement”).
The Agreement sets forth the understanding of the
Parties with respect to the formation of a new Joint Venture called “Insulinova, Inc.” (the “Insulinova”), and
contribute the proprietary rights, know-how, resources and funding as described in the License Agreement.
Austrianova is a cutting-edge Biotech company based
in Singapore embracing leading world quality standards to produce cell-based products. Austrianova’s expertise and technologies
are backed up by more than 50 international peer reviewed publications, as well as by contracts from leading pharmaceutical and biotech
companies. Austrianova’s scientists are experts in cell biology, GMP-grade cell products and encapsulation of living cells. Austrianova
has developed a proprietary cell encapsulation technology to protect, isolate, store, and transport living cells, as well as offering
cell line development and GMP Manufacturing capabilities and expertise and it intends to contribute its intellectual property, know- how,
and resources to Insulinova to achieve the purposes of the Agreement.
AVAI will contribute all of the resources and capital
required by Insulinova, Inc’s formation and operation for the next eighteen (18) months, not to exceed $1.5 million USD in capital
and its resources in exchange for the common stock of Insulinova. AVAI will use its best efforts to assist in arranging additional funding
as needed, as described in the Agreement, at no cost to Austrianova.
The ownership of Insulinova shall be 50% AVAI and
50% Austrianova. The Insulinova will be governed and operated pursuant to the terms of a limited liability company agreement.
The foregoing descriptions of the Joint Venture and
License Agreement are qualified in their entirety by reference to the full text of such agreement, copy of which are attached hereto as
Exhibit 10.1, and which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in
such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to
such agreements, and may be subject to limitations agreed upon by the contracting parties.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking
statements, including statements concerning future financing arrangements and the Company’s business strategy. These statements
are based on current expectations and assumptions and involve risks and uncertainties. Actual results may differ materially from those
described in the forward-looking statements. The Company undertakes no obligation to update any forward-looking statements to reflect
events or circumstances after the date hereof, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description |
| 10.1 |
Joint Venture and License Agreement dated November 1, 2025 |
SIGNATURES
In accordance with the requirements of the Securities Act of 1933, the
registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: November 4, 2025
| |
|
|
| AVANT TECHNOLOGIES INC. |
| |
| By: |
/s/ |
Vitalis Racius |
| |
Name: |
Vitalis Racius |
| |
Title: |
Chief Financial Officer, Director & Treasurer |
| |
|
|
